Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.74 USD -0.93 (-1.56%)
Official Closing Price Updated: 7:59 PM EDT, Oct 27, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,008,200
Open 59.26
Bid (Size) 58.55 (6)
Ask (Size) 58.90 (9)
Prev. Close 59.67
Today's Range 58.56 - 59.84
52wk Range 45.76 - 68.34
Shares Outstanding 1,634,538,458
Dividend Yield 2.72%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Decreases in Americans' Primary Care Visits May Lead to Late Diagnoses of Potentially Serious Conditions1
BMS–Pfizer Alliance, with the support of leading advocacy organizations and medical societies, announce the launch of the No Time to Wait campaign. 
From Business Wire News Releases
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert

Performance

YTD
-7.26%
-7.26%
1 Month
-1.62%
-1.62%
3 Month
-1.16%
-1.16%
6 Month
-5.47%
-5.47%
1 Year
+5.67%
+5.67%

More News

Read More
Promising New Cancer Treatments Advancing Through The Pipeline In Over $200 Billion Dollar Drug Market
From PR Newswire
Top Pharmaceutical Stocks To Capitalize On U.S. Vaccine Hopes
From Stockmarket.com
America’s top CEOs are opening up their wallets for Mitch McConnell’s re-election campaign
Tags CVX BMY SPX
From MarketWatch
XLV, JNJ, ABBV, BMY: ETF Outflow Alert
Tags ETFs
From ETF Channel
Cramer Weighs In On Corsair, Marvell And More
Tags Market News BMY RPRX
From Benzinga
U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma
From Business Wire News Releases
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
From Business Wire News Releases
Healthcare To Post Solid Q3 Earnings Growth: ETFs in Focus
Tags ETFs Healthcare Stocks / Equities
From Blogs - TalkMarkets
'Halftime Report' Traders Share Their Thoughts On Guggenheim's Bristol-Myers Call
Tags Jenny Harrington Jon Najarian BMY
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.